University of Michigan - Brighton Center for Specialty Care

Summary

University of Michigan - Brighton Center for Specialty Care is a medical facility located in Brighton, Michigan. This center is recognized for care of Pancreatic Cancer, Breast Cancer, Breast cancer, Cancer, Prostate Cancer and other specialties. University of Michigan - Brighton Center for Specialty Care is involved with conducting 24 clinical trials across 161 conditions. There are 17 research doctors associated with this hospital, such as Vaibhav Sahai, MBBS, MS, Francis P. Worden, Zachery R. Reichert, and Angel Qin.

Top PIs

Clinical Trials running at University of Michigan - Brighton Center for Specialty Care

Skin Cancer

Ovarian Cancer

Breast Cancer

Pancreatic Cancer

Breast cancer

Bladder Cancer

Oropharyngeal Carcinoma

Lung Cancer

Prostate Cancer

Kidney Cancer

Cemiplimab + Surgery

for Advanced Skin Cancer

This phase III trial compares the effect of adding cemiplimab to standard therapy (surgery with or without radiation) versus standard therapy alone in treating patients with stage III/IV squamous cell skin cancer that is able to be removed by surgery (resectable) and that may have come back after a period of improvement (recurrent). The usual treatment for patients with resectable squamous cell skin cancer is the removal of the cancerous tissue (surgery) with or without radiation, which uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cemiplimab has been approved for the treatment of skin cancer that has spread or that cannot be removed by surgery, but it has not been approved for the treatment of skin cancer than can be removed by surgery. Adding cemiplimab to the usual treatment of surgery with or without radiation may be more effective in treating patients with stage III/IV resectable squamous cell skin cancer than the usual treatment alone.

Recruiting

2 awards

Phase 3

7 criteria

Encorafenib/Binimetinib/Nivolumab vs Ipilimumab/Nivolumab

for Melanoma

This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ipilimumab and nivolumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. This trial aims to find out which approach is more effective in shrinking and controlling brain metastases from melanoma.

Recruiting

1 award

Phase 2

23 criteria